See analyst estimates and all valuation multiples for Genomics & Personalized Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $22.1B | 12.0x | -87.4x | |
| $16.4B | 3.8x | 14.3x | |
| $11.9B | 4.0x | 31.1x | |
| $6.9B | 8.5x | -28.7x | |
| $2.6B | 7.6x | 109.6x | |
| $2.4B | 4.3x | 63.2x | |
| $2.2B | 2.4x | 13.7x | |
| $2.0B | 5.5x | -14.9x | |
| $1.9B | 4.1x | 18.8x | |
| $1.1B | 8.3x | -1.2x | |
| $1.1B | 1.8x | 18.7x | |
| $1.1B | 1.8x | -7.4x | |
| $870M | 2.5x | 29.4x | |
| $743M | 4.8x | -3.4x | |
| $594M | 1.9x | 11.0x | |
| $581M | 14.7x | -2.4x | |
| $567M | 73.2x | -6.2x | |
| $550M | 0.7x | 17.6x | |
| $546M | 9.1x | n/a | |
| $440M | 5.2x | -6.3x | |
| $338M | 1.1x | 8.3x | |
| $295M | 37.8x | -1.6x | |
| $286M | 1.0x | -24.7x | |
| $281M | 85.4x | n/a | |
| $250M | 40.6x | -72.4x | |
| $234M | 18.8x | n/a | |
| $195M | n/a | n/a | |
| $183M | 72.7x | -10.0x | |
| $178M | n/a | n/a | |
| $168M | 2.4x | -4.3x | |
| $163M | n/a | n/a | |
| $132M | 2.4x | -2.0x | |
| $82.6M | n/a | -0.6x | |
| $80.3M | 16.5x | -0.5x | |
| $58.6M | 7.3x | -0.4x | |
| $58.2M | 1.2x | 8.9x | |
| $46.3M | n/a | -0.5x | |
| $43.2M | 16.4x | n/a | |
| $36.3M | n/a | -0.4x | |
| $23.9M | n/a | -0.2x | |
| $17.4M | n/a | n/a | |
| $11.3M | 0.4x | -0.2x | |
| $8.7M | n/a | n/a | |
| $1.0M | 0.0x | -0.0x | |
| $0.2M | 0.0x | -0.0x | |
| -$2.6M | -0.1x | 0.0x | |
| -$3.1M | n/a | n/a | |
| -$5.0M | n/a | 0.1x | |
| -$10.8M | -7.5x | 0.2x | |
| -$17.7M | n/a | n/a | |
| -$30.2M | -0.5x | 0.3x | |
| -$49.8M | -2.9x | n/a | |
| -$65.1M | -6.7x | 0.4x | |
| -$67.8M | -1.2x | n/a | |
| -$127M | -3.1x | 1.3x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Genomics & Personalized Medicine